KOSDAQ - Delayed Quote KRW

iNtRON Biotechnology, Inc. (048530.KQ)

Compare
3,575.00
-25.00
(-0.69%)
At close: 3:30:05 PM GMT+9
Loading Chart for 048530.KQ
  • Previous Close 3,600.00
  • Open 3,550.00
  • Bid 3,565.00 x --
  • Ask 3,575.00 x --
  • Day's Range 3,475.00 - 3,620.00
  • 52 Week Range 3,350.00 - 7,110.00
  • Volume 81,990
  • Avg. Volume 144,249
  • Market Cap (intraday) 113.285B
  • Beta (5Y Monthly) 0.64
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield 100.00 (2.68%)
  • Ex-Dividend Date Dec 27, 2024
  • 1y Target Est --

iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.

www.intron.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 048530.KQ

View More

Performance Overview: 048530.KQ

Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

048530.KQ
36.27%
KOSPI Composite Index (^KS11)
4.41%

1-Year Return

048530.KQ
48.05%
KOSPI Composite Index (^KS11)
15.21%

3-Year Return

048530.KQ
82.85%
KOSPI Composite Index (^KS11)
15.06%

5-Year Return

048530.KQ
72.55%
KOSPI Composite Index (^KS11)
24.91%

Compare To: 048530.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 048530.KQ

View More

Valuation Measures

Annual
As of 4/8/2025
  • Market Cap

    114.08B

  • Enterprise Value

    65.55B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    18.40

  • Price/Book (mrq)

    1.36

  • Enterprise Value/Revenue

    10.21

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -40.37%

  • Return on Assets (ttm)

    -3.54%

  • Return on Equity (ttm)

    -2.87%

  • Revenue (ttm)

    6.42B

  • Net Income Avi to Common (ttm)

    -2.59B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    49.78B

  • Total Debt/Equity (mrq)

    1.49%

  • Levered Free Cash Flow (ttm)

    -562.47M

Research Analysis: 048530.KQ

View More

Company Insights: 048530.KQ

Research Reports: 048530.KQ

View More

People Also Watch